Key Developments: USANA Health Sciences Inc (USNA.N)
72.92USD
4:01pm EDT
$-1.66 (-2.23%)
$74.58
$74.50
$75.72
$72.20
40,874
24,025
$75.98
$30.67
Latest Key Developments (Source: Significant Developments)
USANA Health Sciences Inc Reiterates FY 2013 Revenue Guidance; Raises FY 2013 EPS Guidance
USANA Health Sciences Inc reiterated consolidated net sales outlook and provided the following updated earnings per share outlook for fiscal 2013: Consolidated net sales between $700 million and $720 million and earnings per share (EPS) between $5.25 and $5.40, versus the previous outlook of between $5.10 and $5.25. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $714 million and EPS of $5.18 for fiscal 2013 Full Article
USANA Health Sciences Inc Issues FY 2013 Guidance Above Analysts' Estimates
USANA Health Sciences Inc announced that for fiscal 2013, it expects consolidated net sales between $700 million and $720 million and earnings per share (EPS) of between $5.10 and $5.25. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $690 million and EPS of $4.84 for fiscal 2013. Full Article
USANA Health Sciences Inc Announces Management Team Transition
USANA Health Sciences Inc announced the reorganization of its management team. Doug Hekking is stepping aside as the Company`s Chief Financial Officer(CFO) to return to a strategic role that will support the Company`s finance and operations groups. Mr. Hekking`s decision to change roles was prompted by his need to attend to family health matters and his desire to serve in a more targeted role within the Company. Paul Jones, who is currently serving as the Company`s Vice President of Human Resources, has been named as interim CFO. Full Article
USANA Health Sciences, Inc. Raises FY 2012 Guidance
USANA Health Sciences, Inc. announced that for fiscal 2012, it expects consolidated net sales between $630-$640 million and earnings per share (EPS) between $4.10 and $4.20. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $620 million and EPS of $3.67 for fiscal 2012. Full Article
USANA Health Sciences, Inc. Increases Share Repurchase Authorization To $50 Million
USANA Health Sciences, Inc. announced that its Board of Directors has authorized an increase in its share repurchase program to $50 million. The updated share repurchase authorization is an increase of $22 million from the $28 million remaining under the prior authorization as of the end of the first quarter of 2012. Repurchases may be made from time to time, in the open market, through block trades or otherwise. The number of shares to be purchased and the timing of purchases will be based on market conditions, the level of cash balances, general business opportunities and other factors. Full Article
USANA Health Sciences, Inc. Raises FY 2012 Guidance
USANA Health Sciences, Inc. announced that for fiscal 2012, it provides updated financial guidance and expects consolidated net sales between $610-$625 million, versus previous outlook of $600-$615 million. Earnings per share between $3.60-$3.70, versus previous outlook of $3.35-$3.45. According to I/B/E/S Estimates, analysts were expecting the Company to report revenues of $610 million and EPS of $3.44 for fiscal 2012. Full Article
USANA Health Sciences, Inc. Issues FY 2012 Guidance; EPS Guidance Below Analysts' Estimates
USANA Health Sciences, Inc. announced that for fiscal 2012, it expects consolidated net sales between $600 million and $615 million and earnings per share between $3.35 and $3.45. According to I/B/E/S Estimates, analysts were expecting the Company to report EPS of $3.52 on revenues of $603 million for fiscal 2012. Full Article
USANA Health Sciences, Inc. Raises FY 2011 Guidance
USANA Health Sciences, Inc. announced that for fiscal 2011, it is raising it's outlook and now project consolidated net sales to be between $577-$581 million, versus previous outlook of $565-$575 million. In addition, it expect to generate earnings per share (EPS) between $3.20-$3.25 versus previous outlook of $3.05-$3.10. According to I/B/E/S Estimates, analysts were expecting the Company to report EPS of $3.10 on revenues of $578 million for fiscal 2011. Full Article
USANA Health Sciences, Inc. Increases Share Repurchase Authorization By $30 Million
USANA Health Sciences, Inc. announced that its board of directors has authorized an additional $30 million in funding for share repurchases of its outstanding common stock. Repurchases may be made from time to time, in the open market, through block trades or otherwise. The number of shares to be purchased and the timing of purchases will be based on market conditions, the level of cash balances, general business opportunities and other factors. $30 million authorization will be in addition to the approximately $6 million that are remaining under the prior authorization as of the end of the second quarter of 2011. Full Article
USANA Health Sciences, Inc. Raises FY 2011 Guidance
USANA Health Sciences, Inc. raised its fiscal 2011 guidance and expects consolidated net sales to be between $565 million and $575 million versus previous guidance of $530 million to $550 million and expects to generate earnings per share (EPS) between $3.05 and $3.10 versus previous guidance of $2.85 to $2.95. According to I/B/E/S Estimates, analysts were expecting the Company to report EPS of $3.10 for fiscal 2011. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
